Payment overview · 2025
General Payments
$501.21
24 reported records · 10 companies
Healthcare provider profile · identity verified
Mohammad M. Yaqub, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTIS, FL · NPI 1164616157
Verified facts
What the public records show
CMS Open Payments records show Mohammad M. Yaqub, M.D. received $501.21 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 399 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $117.06 | 23.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.74 | 18.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.33 | 12.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.36 | 11.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.83 | 9.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.77 | 7.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.04 | 7.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.72 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.04 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.32 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $501.21 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.06 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.06 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.46 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.33 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 399 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
399 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 109 |
| Eliquis | Apixaban | 399 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 51 |
| Carvedilol | Carvedilol | 215 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 38 |
| Metformin Hcl | Metformin Hcl | 206 | 46 |
| Gabapentin | Gabapentin | 184 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 62 |
| Potassium Chloride | Potassium Chloride | 162 | 39 |
| Losartan Potassium | Losartan Potassium | 148 | 45 |
| Furosemide | Furosemide | 140 | 44 |
| Permethrin | Permethrin | 125 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 37 |
| Sertraline Hcl | Sertraline Hcl | 121 | 31 |
| Trazodone Hcl | Trazodone Hcl | 119 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 21 |
| Famotidine | Famotidine | 117 | 36 |
| Lisinopril | Lisinopril | 114 | 33 |
| Latanoprost | Latanoprost | 112 | 17 |
| Memantine Hcl | Memantine Hcl | 103 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 21 |
| Donepezil Hcl | Donepezil Hcl | 100 | 24 |
| Lactulose | Lactulose | 91 | 21 |
| Finasteride | Finasteride | 90 | 13 |
| Omeprazole | Omeprazole | 83 | 23 |
| Levetiracetam | Levetiracetam | 82 | 20 |
| Jardiance | Empagliflozin | 79 | 13 |
| Mirtazapine | Mirtazapine | 79 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 17 |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 23 |
| Insulin Aspart Flexpen | Insulin Aspart | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 18 |
| Divalproex Sodium | Divalproex Sodium | 58 | 12 |
| Glipizide | Glipizide | 56 | 14 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | 12 |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 53 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 52 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 23 |
| Midodrine Hcl | Midodrine Hcl | 46 | suppressed |
| Azithromycin | Azithromycin | 43 | 37 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 29 |
| Nystatin | Nystatin | 43 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 22 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Cefdinir | Cefdinir | 36 | 33 |
| Risperidone | Risperidone | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Budesonide | Budesonide | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 11 |
| Spironolactone | Spironolactone | 32 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Xifaxan | Rifaximin | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 22 |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Glucagon Emergency Kit | Glucagon | 24 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 16 |
| Mupirocin | Mupirocin | 23 | 12 |
| Vancomycin Hcl | Vancomycin Hcl | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | 21 |
| Topiramate | Topiramate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | 12 |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | 13 |
| Scopolamine | Scopolamine | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Cefepime | Cefepime In Iso-Osm Dextrose | 11 | suppressed |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $501.21 · 24 records | ABBVIE INC. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, JYNARQUE, NURTEC ODT, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, UBRELVY, Veozah, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error